SARS-CoV-2 3CLpro Mutations T21I and E166A Confer Differential Resistance to Simnotrelvir, Bofutrelvir, and Ensitrelvir

Scientists first investigated the resistance profile of simnotrelvir, an approved anti-SARS-CoV-2 drug that targets 3CLpro. They found that the T21I/E166A mutations in 3CLpro equally emerged when SARS-CoV-2 was passaged in the cells with increasing concentrations of simnotrelvir.